ARS Pharmaceuticals, Inc. (SPRY) Stock Price & Analysis
ARS Pharmaceuticals, Inc. (SPRY) closed at USD 4.07 on Thursday, October 15, 2026, up 3.56% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 3.93; the Oct 15, 2026 session ranged USD 3.94–4.1 on volume of 2,220,029 shares. Market capitalization is $404.75M, with a 52-week range of USD 3.89–13.15 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SPRY.md
Key facts (SPRY)
- 1 of 80 tracked superinvestors hold SPRY (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 22.5 (range 15–30).
- Total return with dividends: 1Y -59.7% vs S&P 500 +18.1%; 5Y -58.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-10, EPS estimate USD -0.33, revenue estimate $42.0M.
Superinvestors (SEC 13F-HR, Q2 2026) (SPRY)
1 of 80 tracked investors hold SPRY. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Daniel Loeb | Third Point | 0.17% | $8.0M | Unchanged |
Analysts (SPRY)
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 22.5 (low 15, high 30).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | Leerink Partners | Target lowered | Outperform | $24 → $18 |
| 2026-06-25 | Leerink Partners | Target lowered | Outperform | $25 → $24 |
Total return (dividends reinvested) (SPRY)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -59.7% | -58.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -59.9% | -16.2% |
| Volatility (annualized) | 74.7% | 68.4% |
| Max drawdown | -69.9% (Jan 2026→Oct 2026) | -77.6% (Jun 2025→Sep 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 4.07 |
|---|---|
| Change | ▲ 3.56% (up) |
| Previous Close | USD 3.93 |
| Open | USD 3.99 |
| Day Range | USD 3.94 – 4.1 |
| 52-Week Range | USD 3.89 – 13.15 |
| Volume | 2,220,029 shares |
| Market Cap | $404.75M |
| Exchange | NGM |
Technical Analysis (SPRY)
Nexqual's technical model rates SPRY "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 36.05 (neutral) |
| vs SMA50 | Below (USD 5.02) |
| MACD | -0.25 (negative) |
Analyst Ratings (SPRY)
Wall Street analysts rate SPRY "Buy" based on 4 analysts, with a mean price target of USD 22.5 (range USD 15–30), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 22.5 |
| High Target | USD 30 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (SPRY)
| Next Earnings Date | 2026-11-10 |
|---|---|
| EPS Estimate | USD -0.33 |
| Revenue Estimate | $41.99M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.63 vs est -0.49 ▼ miss |
| 2026-03-31 | USD -0.61 vs est -0.54 ▼ miss |
| 2025-12-31 | USD -0.42 vs est -0.48 ▲ beat |
| 2025-09-30 | USD -0.52 vs est -0.49 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (SPRY)
| Total Revenue | $116.93M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +114.20% |
| Gross Margin | +58.35% |
| Operating Margin | -182.62% |
| Profit Margin | -184.24% |
| ROE | -210.35% |
| Debt / Equity | 13.72 |
| Current Ratio | 3.48 |
| Total Cash | $143.84M |
| Total Debt | $171.60M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$171.21M (-203.1% of revenue) |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (SPRY)
Nexqual rates ARS Pharmaceuticals, Inc.'s overall financial health "Critical" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Weak — Revenue -5% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $144M cash vs $172M debt |
| Cash Flow | Weak — FCF negative: -$171M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -210%, ROA -48.0% |
Ownership (SPRY)
| Insider Ownership | +16.18% |
|---|---|
| Institutional Ownership | +92.12% |
| Shares Outstanding | 99.45M |
| Float | 48.03M |
| Short % of Float | +30.72% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (SPRY)
ARS Pharmaceuticals, Inc. is led by Donn Casale (age 52), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO, President & Director | Donn Casale (age 52) |
|---|---|
| Chief Financial Officer | Kathleen D. Scott |
| Chief Operating Officer | Brian T. Dorsey M.S. (age 56) |
| Senior Vice President of Marketing | Daniel Relovsky |
| Vice President of Human Resources | Lynda Harris |
Major Backers & Investors (SPRY)
Notable institutional backers of ARS Pharmaceuticals, Inc. include RA Capital Management, L.P., Rubric Capital Management LP, Orbimed Advisors LLC., according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 10.92% |
| Rubric Capital Management LP | 8.59% |
| Orbimed Advisors LLC. | 8.33% |
| Deerfield Management Company, L.P | 7.55% |
| Tyro Capital Management LLC | 4.48% |
| Aberdeen Group plc | 4.19% |
| SR One Capital Management, LP | 4.04% |
| abrdn Healthcare Opportunities Fund | 3.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.93% |
| State Street | 5.94% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt